Drug Profile
CIGB 370
Alternative Names: CIGB-370Latest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Sep 2023 Discontinued - Preclinical for Cancer in Cuba (IV)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cancer in Cuba (IV, Infusion)
- 01 Feb 2016 Preclinical trials in Cancer in Cuba (IV) before February 2016 (RPCEC00000209)